Hey traders, it’s Alfonso Moreno from Set and Forget! Today, I’m diving into one of the most famous pharmaceutical giants on the planet — Pfizer. Yes, that Pfizer. Love them or hate them, the chart doesn’t lie. The weekly timeframe just gave us a brand-new demand imbalance, and it’s looking ready to roar. Let’s break it down and see if Pfizer could be preparing for a bullish comeback.
The New Weekly Demand Imbalance
We’ve got a fresh weekly demand imbalance trading between $24.39 and $23.58, and it’s already gained control. This is the largest bullish candlestick in months — a clear reaction showing professional buying pressure stepping in after months of drifting lower.
The beauty of this setup?
The risk is under $1, which makes it a tight and well-defined imbalance — a pocket of price where institutions previously decided to buy aggressively.
The New Weekly Demand Imbalance
We’ve got a fresh weekly demand imbalance trading between $24.39 and $23.58, and it’s already gained control. This is the largest bullish candlestick in months — a clear reaction showing professional buying pressure stepping in after months of drifting lower.
The beauty of this setup?
The risk is under $1, which makes it a tight and well-defined imbalance — a pocket of price where institutions previously decided to buy aggressively.
Alfonso Moreno
Set and Forget Trading Community
Set and Forget Trading Community
Clause de non-responsabilité
Les informations et les publications ne sont pas destinées à être, et ne constituent pas, des conseils ou des recommandations en matière de finance, d'investissement, de trading ou d'autres types de conseils fournis ou approuvés par TradingView. Pour en savoir plus, consultez les Conditions d'utilisation.
Alfonso Moreno
Set and Forget Trading Community
Set and Forget Trading Community
Clause de non-responsabilité
Les informations et les publications ne sont pas destinées à être, et ne constituent pas, des conseils ou des recommandations en matière de finance, d'investissement, de trading ou d'autres types de conseils fournis ou approuvés par TradingView. Pour en savoir plus, consultez les Conditions d'utilisation.